IP Library Granted Patent US 10,449,203
Granted Patent B2
US 10,449,203 · App. 15/856,818 · Granted Oct 22, 2019

Tianeptine oxalate salts and polymorphs

Inventors: Stefano Luca Giaffreda (Bologna, IT); Enrico Modena (Bologna, IT); Serena Fabbroni (Medicina, IT); Michel Chiarucci (Bologna, IT); Mark T. Edgar (Rancho Santa Fe, CA)
Assignee: Tonix Pharma Holdings Limited
A61K31/554C07D281/02A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,449,203
App. No.
15/856,818
Granted
Oct 22, 2019
Kind
B2
Abstract

Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:

Claims (6)

1. An anhydrous crystalline hemi-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the salt exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from the group consisting of 8.2, 8.6, 9.1, and 9.5 degrees 2θ±0.3 degrees 2θ.

2. The compound of claim 1 , wherein the tianeptine hemi-oxalate salt exhibits an XRPD pattern comprising at least one additional peak selected from the group consisting of 4.5, 11.5, 14.2, 15.2, 15.8, 16.4, 19.2, 22.1, 23.9, 26.9, and 27.4 degrees 2θ±0.3 degrees 2θ.

3. An anhydrous crystalline tianeptine mono-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the salt exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from the group consisting of 10.1 and 10.5 degrees 2θ±0.3 degrees 2θ.

4. The compound of claim 3 , wherein the crystalline tianeptine mono-oxalate salt exhibits an XRPD pattern comprising at least one additional peak selected from the group consisting of 7.5, 8.3, 11.9, 14.7, 16.2, 16.3, 17.9, 18.7, 21.0, 21.7, and 22.1 degrees 2θ±0.3 degrees 2θ.

5. A mixture of an anhydrous hemi-oxalate salt and an anhydrous crystalline mono-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the mixture exhibits an XRPD pattern comprising at least one peak selected from the group consisting of 10.1 and 10.5 degrees 2θ±0.3 degrees 2θ.

6. The mixture of claim 5 , wherein the mixture exhibits an XRPD pattern further comprising at least one additional peak selected from the group consisting of 7.5, 8.3, 11.9, 14.7, 16.2, 16.3, 17.9, 18.7, 21.0, 21.7, and 22.1 degrees 2θ±0.3 degrees 2θ.

Assignments (5)
NOVATION AGREEMENT Recorded Sep 25, 2024
From: TONIX PHARMA HOLDINGS LIMITED
To: TONIX PHARMA LIMITED
Reel/Frame 069504/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2017
From: EDGAR, MARK T.
To: TONIX PHARMACEUTICALS, INC.
Reel/Frame 044504/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2017
From: GIAFFREDA, STEFANO LUCA; MODENA, ENRICO; FABBRONI, SERENA; CHIARUCCI, MICHEL
To: POLYCRYSTALLINE S.P.A.
Reel/Frame 044504/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2017
From: TONIX PHARMACEUTICALS, INC.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 044988/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2017
From: POLYCRYSTALLINE S.P.A.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 044996/0612 →
Continuity (2)
Provisional Application 62439533 · Dec 28, 2016
Related Publication 20180338984A1 · Nov 29, 2018